Business
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) to address significant unmet medical needs Ongoing development of PALI-2108 across FSCD and UC, with Phase 2 IND submission planned for H1 2026 Carlsbad, CA, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-ge
About this update from Palisade Bio, Inc.
[{"type":"image","alt":"Palisade Bio, Inc.","displaySize":"","headline":null,"caption":"Palisade Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":77,"url":"https://media.zenfs.com/en/globenewswire.com/2a3a6d9c80425bf813c98abfe355e747"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VBDa4YPveOaoDW8bYlQJUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2a3a6d9c80425bf813c98abfe355e747","width":300,"height":77}},"lazy":false},{"type":"text","content":"PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) to address significant unmet medical needs Ongoing development of PALI-2108 across FSCD and UC, with Phase 2 IND submission planned for H1 2026","length":328,"tagName":"p"},{"type":"text","content":"Carlsbad, CA, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that the Japan Patent Office (JPO) has granted a key patent covering PALI-2108, the Company’s lead, gut-microbiota-activated PDE4 B/D inhibitor being advanced for fibrostenotic Crohn’s disease (FSCD) and moderate to severe ulcerative colitis (UC).","length":552,"tagName":"p"},{"type":"text","content":"The patent, titled “Gut Microbiota-Activated PDE4 Inhibitor Prodrug,” provides composition-of-matter protection for PALI-2108 in Japan. The base patent term extends into 2041 and is eligible for patent term extension based on regulatory review timelines. This issuance expands Palisade Bio’s growing global intellectual property estate supporting PALI-2108 and its broader platform of locally activated PDE4 inhibitor prodrugs.","length":427,"tagName":"p"},{"type":"text","content":"“Securing this Japanese patent for PALI-2108 is an important milestone as we continue to strengthen the IP foundation for our IBD portfolio,” said J.D. Finley, Chief Executive Officer of Palisade Bio. “Japan represents one of the world’s largest and most commercially significant markets for inflammatory bowel disease, and patients with UC and FSCD continue to face limit...